Edwards Lifesciences (EW) fundamentals: P/E, valuation, undervalued?
Edwards Lifesciences · Health Care · ref. ETF XLV · price $85.27
In short — Edwards Lifesciences trades at 50.8× earnings (P/E), 25.2× forward, with a net margin of 15.4 % and revenue growth of +14 %. Read: Fairly valued (P/E 25 in line with ~14% growth (PEG 1.9)).
Is Edwards Lifesciences stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$85.27+16.2% over range
Oct 14, 25low $72.65 · high $95.18Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
77% recommend buying · 13 analysts
Valuation : Fairly valued — P/E 25 in line with ~14% growth (PEG 1.9)
Valuation
50.8
P/E (price/earnings)
25.2
Forward P/E
—
PEG
4.6
Price/book (P/B)
$49.1B
Market cap
1.68
EPS
Profitability & growth
15.4 %
Net margin
+14 %
Revenue growth
-25 %
Earnings growth
$704M
Total debt
Edwards Lifesciences income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $5.4B | $1.5B | 28.3 % |
| 2023 | $6.0B | $1.4B | 23.4 % |
| 2024 | $5.4B | $4.2B | 76.7 % |
| 2025 | $6.1B | $1.1B | 17.7 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Edwards Lifesciences's P/E and is the stock undervalued? What's a good P/E?
Edwards Lifesciences's P/E is 50.8 (forward 25.2). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Fairly valued".
Is Edwards Lifesciences profitable?
Edwards Lifesciences has a net margin of 15.4 % (EPS 1.68). The company is profitable.
Is EW stock expensive?
Our read: "Fairly valued" — P/E 25 in line with ~14% growth (PEG 1.9). Cross-check with growth and sector.
💬 A question about Edwards Lifesciences? The JPI assistant answers using our backtest data.
Keep exploring Edwards Lifesciences